CMV-Specific CD8+ T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation

被引:32
|
作者
Westall, G [1 ]
Kotsimbos, T
Brooks, A
机构
[1] Alfred Hosp, Dept Allergy Immunol & Resp Med, Lung Transplant Unit, Melbourne, Vic, Australia
[2] Monash Univ, Sch Med, Clayton, Vic 3168, Australia
[3] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia
关键词
bronchoalveolar lavage; CD8(+) T cells; cytomegalovirus; lung transplantation; MHC class I tetramers;
D O I
10.1111/j.1600-6143.2005.01212.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Despite the potentially high burden of cytomegalovirus (CMV)-related disease following lung transplantation, the role of the cytotoxic T-lymphocyte (CTL) response to CMV in this patient group is ill-defined. We assessed the CMV-specific T-cell response in the blood and lung allograft of immunosuppressed lung transplant recipients receiving antiviral prophylaxis and following their withdrawal. While the proportion of CMV-specific CTL varied between patients, in the absence of CMV reactivation the level of CMV-specific CD8(+) T cells in the blood remained stable over time. In the majority of patients CMV-specific cells could be detected in the lung allograft, often in the absence of viral DNA. Additionally, following primary CMV lung infection, CMV-specific CD8(+) T cells were detected no earlier than 100 days post-transplantation but still prior to the detection of viral DNA in the lung allograft. Together these findings suggest that very low levels of CMV replication are sufficient to both prime and recruit CMV-specific CD8(+) T cells to the MHC-mismatched lung allograft. The direct detection of CMV-specific T cells with an effector phenotype in the lung allograft suggests a protective antiviral function. This study provides a framework upon which the association between CMV and chronic allograft rejection can be further studied.
引用
收藏
页码:577 / 584
页数:8
相关论文
共 50 条
  • [31] Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events
    Ralph Rogers
    Kapil Saharia
    Aditya Chandorkar
    Zoe F. Weiss
    Kendra Vieira
    Sophia Koo
    Dimitrios Farmakiotis
    BMC Infectious Diseases, 20
  • [32] Monitoring cytomegalovirus IE-1 and PP65-Specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations
    Gratama, Jan W.
    Brooimans, Rik A.
    van der Holt, Bronno
    Sintnicolaas, Kees
    van Doornum, Gerard
    Niesters, Huberrus G.
    Lowenberg, Bob
    Cornelissen, Jan J.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2008, 74B (04) : 211 - 220
  • [33] CD154 Deficiency Uncouples Allograft CD8+ T-Cell Effector Function from Proliferation and Inhibits Murine Airway Obliteration
    Shah, P. D.
    West, E. E.
    Whitlock, A. B.
    Orens, J. B.
    McDyer, J. F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (12) : 2697 - 2706
  • [34] Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection
    Zandvliet, Maarten L.
    Falkenburg, J. H. Frederik
    van Liempt, Ellis
    Veltrop-Duits, Louise A.
    Lankester, Arjan C.
    Kalpoe, Jayant S.
    Kester, Michel G. D.
    van der Steen, Dirk M.
    van Tol, Maarten J.
    Willemze, Roel
    Guchelaar, Henk-Jan
    Schilham, Marco W.
    Meij, Pauline
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1943 - 1951
  • [35] Long-term efficacy of CMV/EBV bivirus-specific T cells for viral co-reactivation after stem cell transplantation
    Pei, Xuying
    Lv, Meng
    Mo, Xiaodong
    Sun, Yuqian
    Chen, Yuhong
    Yan, Chenhua
    Zhang, Yuanyuan
    Xu, Lanping
    Wang, Yu
    Zhang, Xiaohui
    Huang, Xiaojun
    Zhao, Xiangyu
    CHINESE MEDICAL JOURNAL, 2025, 138 (05) : 607 - 609
  • [36] Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation
    Carvalho-Gomes, Angela
    Cubells, Almudena
    Pallares, Carmina
    Corpas-Burgos, Francisca
    Berenguer, Marina
    Aguilera, Victoria
    Lopez-Labrador, F. Xavier
    CELLULAR IMMUNOLOGY, 2022, 371
  • [37] Cytomegalovirus replication is associated with enrichment of distinct g 8 T cell subsets following lung transplantation: A novel therapeutic approach?
    Stankovic, Sanda
    Davey, Martin S.
    Shaw, Evangeline M.
    von Borstel, Anouk
    Cristiano, Yvonne
    Levvey, Bronwyn J.
    Rossjohn, Jamie
    Westall, Glen P.
    Snell, Gregory I.
    Brooks, Andrew G.
    Sullivan, Lucy C.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (11) : 1300 - 1312
  • [38] Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+ T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation
    Gimenez, E.
    Munoz-Cobo, B.
    Solano, C.
    Amat, P.
    de la Camara, R.
    Nieto, J.
    Lopez, J.
    Remigia, M. J.
    Garcia-Noblejas, A.
    Navarro, D.
    TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (03) : 361 - 370
  • [39] The CD8+ T cell content of transbronchial biopsies from patients with a first episode of clinically stable grade A1 cellular rejection is associated with future chronic lung allograft dysfunction1
    Beber, Samuel A.
    Moshkelgosha, Sajad
    White, Matthew
    Zehong, Guan
    Cheung, May
    Hedley, David
    Levy, Liran
    Samuels, Joel
    Renaud-Picard, Benjamin
    Hwang, David
    Martinu, Tereza
    Juvet, Stephen
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (10) : 1654 - 1664
  • [40] Optimal CD8+ T-cell memory formation following subcutaneous cytomegalovirus infection requires virus replication but not early dendritic cell responses
    Dimonte, Sandra
    Gimeno-Brias, Silvia
    Marsden, Morgan
    Chapman, Lucy
    Sabberwal, Pragati
    Clement, Mathew
    Humphreys, Ian R.
    IMMUNOLOGY, 2021, 164 (02) : 279 - 291